Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Tivozanib Hydrochloride|DRUG: paclitaxel|DRUG: Placebo
Sponsor: AVEO Pharmaceuticals, Inc.
Collaborators: Astellas Pharma Inc